13 records – page 1 of 1.

Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy11514
Last Reviewed
2020-02-29
Date
2015-02-28
Topics
Pharmaceuticals, prescribing, cannabis, drugs
POLICY Authorizing Cannabis for Medical Purposes The legalization of cannabis for recreational purposes came into effect with the Cannabis Act in October 2018, and patients continue to have access to cannabis for therapeutic purposes. The Cannabis Regulations 1 have replaced the Access
Policy Type
Policy document
Last Reviewed
2020-02-29
Date
2015-02-28
Topics
Pharmaceuticals, prescribing, cannabis, drugs
Documents
Less detail

Bill C-45: The Cannabis Act

https://policybase.cma.ca/link/policy13723
Date
2017-08-18
Topics
Pharmaceuticals, prescribing, cannabis, drugs
CMA Submission: Bill C-45: The Cannabis Act Submission to the House of Commons Standing Committee on Health August 18, 2017 The Canadian Medical Association (CMA) is the national

Bill C-45: The Cannabis Act

https://policybase.cma.ca/link/policy13861
Date
2018-04-18
Topics
Pharmaceuticals, prescribing, cannabis, drugs
CMA Submission: Bill C-45: The Cannabis Act Submission to the Senate Standing Committee, Social Affairs, Science &Technology April 18th, 2018

Canada’s lower-risk cannabis use guidelines (LRCUG)

https://policybase.cma.ca/link/policy13726
Date
2017-05-26
Topics
Pharmaceuticals, prescribing, cannabis, drugs
Canada’s Lower-Risk Cannabis Use Guidelines (LRCUG) Recommendations • Cannabis use has health risks best avoided by abstaining • Delay taking up cannabis use until later in life • Identify and choose lower-risk cannabis products • Don’t use synthetic cannabinoids • Avoid smoking

Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy10045
Last Reviewed
2019-03-03
Date
2010-12-04
Topics
Pharmaceuticals, prescribing, cannabis, drugs
CMA POLICY Cannabis for Medical Purposes CMA Position: The Canadian Medical Association (CMA) has always recognized the unique requirements
Policy Type
Policy document
Last Reviewed
2019-03-03
Date
2010-12-04
Topics
Pharmaceuticals, prescribing, cannabis, drugs
Documents
Less detail

CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13641
Date
2017-04-07
Topics
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs
be purchased. The more restricted is availability, the easier it is to regulate. The CMA considers prohibiting the promotion of flavours in vaping products that may appeal to youth, such as soft drinks and cannabis, to be a positive step. A recent report published by the World Health Organization

CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13918
Date
2018-02-15
Topics
Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety
that may appeal to youth, such as soft drinks and cannabis, to be a positive step. A recent report published by the World Health Organization and the US National Cancer Institute indicated that websites dedicated to retailing e-cigarettes “contain themes that may appeal to young people, including images

Excise duty framework for cannabis products

https://policybase.cma.ca/link/policy13799
Date
2017-12-07
Topics
Pharmaceuticals, prescribing, cannabis, drugs
CMA Submission: Excise Duty Framework for Cannabis Products Submission to the Government of Canada consultation on the proposed excise duty framework for cannabis products December 7, 2017

Health Canada consultation on Canadian drugs and substances strategy

https://policybase.cma.ca/link/policy14017
Date
2018-12-04
Topics
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
? Training for police and other frontline criminal justice and corrections workers in how to interact with people with substance use issues is essential. The CMA believes that the government must take a broad public health policy approach. Changes to the criminal law affecting cannabis must not promote

Health Canada consultation on potential market for cannabis health products that would not require practitioner oversight

https://policybase.cma.ca/link/policy14125
Date
2019-09-03
Topics
Health care and patient safety
Population health, health equity, public health
CMA response: HEALTH CANADA CONSULTATION ON POTENTIAL MARKET FOR CANNABIS HEALTH PRODUCTS THAT WOULD NOT REQUIRE PRACTITIONER OVERSIGHT September 03, 2019

The Health risks and harms associated with the use of marijuana

https://policybase.cma.ca/link/policy11138
Date
2014-05-27
Topics
Pharmaceuticals, prescribing, cannabis, drugs
. The Canadian Medical Association (CMA) is pleased to present this brief to the House of Commons Standing Committee on Health for consideration as part of its study on the health risks and harms associated with the use of marijuana. Marijuana, or cannabis, is a Schedule II drug under the Canadian

Legalization, regulation and restriction of access to marijuana

https://policybase.cma.ca/link/policy11954
Date
2016-08-29
Topics
Pharmaceuticals, prescribing, cannabis, drugs
Cannabis Use Guidelines for Canadag 27 should be discussed, particularly with teens, in an effort to minimize harm, even if they choose to continue to use. It is important that these education programs be designed by governments and health professionals, and not marijuana producers or distributers

Proposed approach to the regulation of cannabis

https://policybase.cma.ca/link/policy13838
Date
2018-01-19
Topics
Pharmaceuticals, prescribing, cannabis, drugs
CMA submission: PROPOSED APPROACH TO THE REGULATION OF CANNABIS Submission to Health Canada January 19, 2018

13 records – page 1 of 1.